UCO
Get informed when a big investor buys or sells
+ Follow| Market cap | $31.66 Billion |
|---|---|
| Enterprise Value | $31.48 Billion |
| Dividend Yield | $- (NaN%) |
| Earnings per Share | $- |
| Beta | 2.82 |
| Outstanding Shares | - |
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2410.83 |
| Enterprise Value to EBIT | -418.83 |
| Enterprise Value to Net Income | -447 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4510▲ 4.70% |
|---|---|
| Total Calls | 2,519,400▲ 31.35% |
| Total Puts | 1,136,200▲ 46.64% |
Holdings and activity of institutional investors.
| Ownership % | 7.28%▲ 4.23% |
|---|---|
| Total Invested | $29.94M▲ 187.93% |
| Investors Holding | 48▲ 1.00% |
No data
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...